Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Fatigue 4 Prostatic Neoplasms 3 Sleep Wake Disorders 2 Neurotoxicity Syndromes 1 Hematologic Neoplasms 1 Depression 1 Cognitive Dysfunction 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 303 Paclitaxel 256 Cyclophosphamide 251 Docetaxel 238 Capecitabine 175 Letrozole 163 Carboplatin 163 Doxorubicin 145 Fulvestrant 144 Bevacizumab 121 Anastrozole 106 Tamoxifen 102 exemestane 94 Vinorelbine 91 Epirubicin 90 pertuzumab 88 Gemcitabine 84 Lapatinib 80 Albumin-Bound Paclitaxel 74 Radiotherapy 71 pembrolizumab 70 palbociclib 64 130-nm albumin-bound paclitaxel 58 eribulin 56 Cisplatin 55 Everolimus 49 pyrotinib 44 Taxes 44 Goserelin 43 Neoadjuvant Therapy 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × Methylphenidate × Clear all

NCT02970500 2023-03-23

CogMet

CHU de Quebec-Universite Laval

Phase 2 Terminated

Breast Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡